EUCTR2016-004778-16-AT进行中（未招募）1 期
Carfilzomib in combination with lenalidomide and dexamethasone – feasibility and efficacy of a new consolidation regimen in inducing and/or re-inducing minimal residual disease negativity in multiple myeloma patients after a first autologous stem cell transplant. A prospective, multicenter, interventional, open label, phase II Trial.
Department of Medicine I, Ordensklinikum Linz, Elisabethinen Hospital Linz0 个研究点目标入组 41 人开始时间: 2017年12月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 41
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Anteceding therapeutic sequence of 4 to 6 cycles of an induction therapy followed by a treatment with high-dose melphalan (HD-MEL) and ASCT
- •- = partial response before HD-MEL
- •- = very good partial response and MRD-positivity after ASCT
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 21
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •One or more of the following ultra-high risk features at first diagnosis:
- •- A Revised International Staging System (R-ISS) score (Palumbo 2015) of III at first diagnosis
- •- Extended extramedullary disease (especially CNS involvement)
- •- Plasma cell leukemia
研究者
相似试验
进行中（未招募）
1 期
Carfilzomib + Lenalidomide +Dexamethasone for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomasBTK inhibitors relapsed-refractory or intolerant mantle cell lymphomasMedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000540-25-ITFONDAZIONE ITALIANA LINFOMI ONLUS59
进行中（未招募）
1 期
Carfilzomib in combination with Thalidomide and Dexamethasone for remission induction and consolidation of Multiple Myeloma at first presentatioMultiple myeloma at first presentationEUCTR2009-014922-40-NLErasmus MC
已完成
2 期
Carfilzomib in combination with Thalidomide and Dexamethasone for remission induction and consolidation of Multiple Myeloma at first presentatio10027656Multiple MyelomaNL-OMON46962Erasmus MC, Universitair Medisch Centrum Rotterdam145
进行中（未招募）
1 期
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patientsEUCTR2013-005157-75-NLHOVON Foundation61
进行中（未招募）
1 期
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patientsPrimary plasma cell leukemiaMedDRA version: 20.0Level: LLTClassification code 10035223Term: Plasma cell leukemiaSystem Organ Class: 100000004864EUCTR2013-005157-75-BEHOVON Foundation61